Generic Name and Formulations:
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
CSL Behring, LLC
Indications for HAEGARDA:
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Adults and Children:
Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). 60 IU/kg twice weekly (every 3 or 4 days).
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Clinical Pain Advisor Articles
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Pediatric Opioid Prescriptions Have Declined Since 2012
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- ACA Coverage Substantial, but Did Not Impact Labor Markets
- AMA to Collect Data on Suicide Among Doctors-in-Training
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety